ReviewCurrent hypertension reports2017
Antihypertensive Therapies and Left Ventricular Hypertrophy.
Review in Current hypertension reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacotherapy for hypertension-induced left ventricular hypertrophy.The Cochrane database of systematic reviews · 2021Pooled it
- Trimetazidine's Anti-ischemic Effectiveness in Patients with Stable Angina with Prior Myocardial Infarction Evaluated via Stress Echocardiography with Speckle Tracking: METHOD study.Cardiology and therapy · 2026Article
- Blood pressure control and left ventricular echocardiographic progression in hypertensive patients: an 18-month follow-up study.Frontiers in cardiovascular medicine · 2023Article
- Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.Pharmacological reviews · 2023Review
- Value of estimated pulse wave velocity to identify left ventricular hypertrophy prevalence: insights from a general population.BMC cardiovascular disorders · 2022Article
- The Traditional Chinese Medicine Gedan Jiangya Decoction Alleviates Left Ventricular Hypertrophy via Suppressing the Ras/ERK1/2 Signaling Pathway.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- The Global Ambulatory Blood Pressure Monitoring (ABPM) in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry. Rationale, design and objectives.Journal of human hypertension · 2021Article
- Certain beta blockers (e.g., bisoprolol) may be reevaluated in hypertension guidelines for patients with left ventricular hypertrophy to diminish the ventricular arrhythmic risk.Journal of human hypertension · 2021Review
- Left Ventricular Mass Reduction by a Low-Sodium Diet in Treated Hypertensive Patients.Nutrients · 2020Article
- Pyroptosis Plays a Role in Osteoarthritis.Aging and disease · 2020Review
- Sodium Intake and Target Organ Damage in Hypertension-An Update about the Role of a Real Villain.International journal of environmental research and public health · 2020Review
- Hypertensive Mediated Organ Damage and Hypertension Management. How to Assess Beneficial Effects of Antihypertensive Treatments?High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2020Review
- Zi Shen Huo Luo Formula Prevents Aldosterone-Induced Cardiomyocyte Hypertrophy and Cardiac Fibroblast Proliferation by Regulating the Striatin-Mediated MR/EGFR/ERK Signaling Pathway.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Crim1 suppresses left ventricular hypertrophy.Biomedical reports · 2019Article
- Is Left Ventricular Hypertrophy a Valid Therapeutic Target?Current hypertension reports · 2019Review
- Role of pyroptosis in cardiovascular disease.Cell proliferation · 2019Review
- Unanswered Questions Regarding Blood Pressure Management for HF Prevention.Current hypertension reports · 2019Review
- Transcriptomic Validation of the Protective Effects of Aqueous Bark Extract ofFrontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIt is widely accepted that successful lowering of blood pressure (BP) in patients with hypertension leads to regression of left ventricular hypertrophy (LVH). However, whether differences exist among pharmacological BP-lowering therapies is debated. In this report, we discuss these differences in light of recent literature and the position of extant practice guidelines. RECENT
findingsStudies comparing the effects of antihypertensive classes on LVH regression reached different conclusions, but the overall direction which is reflected in current society guidelines is that successful lowering of BP is more important than selection of an individual antihypertensive class. Nevertheless, some practice guidelines added statements about considering a specific antihypertensive class for its potential benefit such as angiotensin-converting enzyme inhibitors and/or excluding a class such as direct vasodilators. On the other hand, reports have been consistent about the more favorable effect of intensive BP-lowering strategy (target systolic BP < 120 mmHg) compared to standard BP lowering (target systolic BP > 140 mmHg), which is not yet discussed in the current practice guidelines. Successful lowering of BP leads to LVH regression. While reports have been inconsistent about differences among antihypertensive classes, lowering BP beyond currently recommended levels has consistently showed a greater effect on LVH regression.
Indexed as
Identifiers
28929454What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.